[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352561-105":59,"doc-detail-352561-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multicancer-detection-assays-promise-and-potential-harms-of-a-novel-cancer-screening-tool","Multicancer Detection Assays - Promise and Potential Harms of a Novel Cancer Screening Tool","","Multicancer detection (MCD) tests are an emerging blood-based cancer screening innovation that may identify multiple cancer types earlier and with broader accessibility than traditional, tumor-specific approaches. Evidence suggests MCD assays can detect cancer signals and sometimes indicate tissue of origin, potentially expanding screening where effective modalities are limited. Key concerns include false positives, emotional distress, unwarranted reassurance from false negatives, overdiagnosis of indolent cancers, and added strain on health systems, with follow-up protocols and harms reporting not yet fully clarified. Equity gaps remain due to limited trial diversity and incomplete population-specific risk capture. Rigorous evaluation and transparent harms reporting, paired with robust follow-up practices and shared decisionmaking, are essential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multicancer-detection-assays-promise-and-potential-harms-of-a-novel-cancer-screening-tool/352561/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multicancer-detection-assays-promise-and-potential-harms-of-a-novel-cancer-screening-tool/352561.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do multicancer detection (MCD) tests work and what do they detect?","Question",{"text":112,"@type":113},"MCD assays use blood samples to analyze circulating cell-free DNA and other circulating tumor fragments. They aim to detect cancer signals and may provide information about the possible origin of the signal.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What benefits do MCD tests offer compared with conventional cancer screening?",{"text":117,"@type":113},"MCD tests may detect multiple cancer types earlier in their course, when treatment is more likely to be effective. Their blood-based approach could also improve accessibility relative to site-specific screening.",{"name":119,"@type":110,"acceptedAnswer":120},"What potential harms and limitations are associated with MCD testing?",{"text":121,"@type":113},"Concerns include false positives causing short-term emotional distress and additional testing that may be wasteful or risky, false negatives leading to unwarranted reassurance, and overdiagnosis of indolent cancers. Limited harms reporting and unclear follow-up protocols further complicate clinical use.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352561,1790195511,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Multicancer Detection Assays: Promise and Potential Harms of a Novel Cancer Screening Tool  \nCaroline M Snead, MD1; Dominick Zheng, MD2; Quyen Ngo-Metzger, MD, MPH3; Michael K Gould, MD, MS3  \nPerm J 2026;30:25.075 • [https://doi.org/10.7812/TPP/25.075](https://doi.org/10.7812/TPP/25.075)  \n MKG, 0000-0001-6749-8315  \nAbstract  \nMulticancer detection (MCD) tests are an emerging innovation in cancer screening that use blood samples to detect multiple cancer types at once, potentially identifying malignancies earlier and with greater accessibility than traditional, site-specific screening methods. Several tests have demonstrated the ability to detect cancer signals and suggest tissue of origin, which may enhance screening for cancers with existing screening tests and fill critical gaps for cancers lacking effective screening modalities. However, MCD testing raises concerns about the potential for substantial harm, including false-positive test results leading to short-term emotional distress and wasteful and potentially risky testing, unwarranted reassurance when results are falsely negative, the identification of indolent cancers (overdiagnosis), and increased strain on health care resources. Unclear follow-up protocols and limited harms reporting further complicate their use. Equity issues persist, as clinical trials may lack diverse representation and potentially miss population-specific risks. To ensure that MCD tests provide a net benefit to patients and to minimize the burden on health systems, rigorous evaluation, transparent harms reporting, and the implementation of robust practices for follow-up and shared decisionmaking are essential. As these tests evolve and their use becomes more widespread, careful integration into existing screening practices will be key to maximizing benefit while minimizing unintended consequences.  \nPoint: Multicancer Detection Assays Are Promising and Likely to Be More Accessible Than Conventional Cancer Screening Tests  \nWHAT IS A MULTICANCER DETECTION TEST?  \nMulticancer detection (MCD) assays represent a promising  \nfrontier in cancer screening, offering the potential to detect multiple types of cancer earlier in their course when treatment is more likely to be effective (Table) . Cell-free DNA (cfDNA) is genetic material from different tissues throughout the body that can be found in the bloodstream and other bodily fluids. Blood-based MCD tests utilize cfDNA and other circulating tumor cell fragments to detect cancer signals across different types of malignant tumors.1 These tests can indicate the presence or absence of a cancer signal  \n84 | THE PERMANENTE JOURNAL  \nPOINT-COUNTERPOINT  \nCorresponding Author Michael K Gould, MD, MS [michael.k.gould@kp.org](michael.k.gould@kp.org)  \nAuthor Affiliations 1 Department of Internal Medicine, University of California, Davis, Sacramento, CA, USA  \n2 Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA  \n3 Department of Health Systems Science, Kaiser Permanente Bernard J Tyson School of Medicine, Pasadena, CA, USA  \nAuthor Contributions  \nCaroline M Snead, MD, Dominick Zheng, MD, and Michael K Gould, MD, MS, contributed to conception. Caroline Snead and Dominick Zheng contributed to literature review and the drafting of the manuscript. Quyen Ngo-Metzger, MD, MPH, and Michael Gould contributed to critical review and revision.  \nDisclosures  \nConflicts of Interest: Dr Gould reports receiving royalties from UpToDate to coauthor topics on lung cancer diagnosis and staging and non-employee compensation from the American Thoracic Society to serve as deputy editor for the Annals of the American Thoracic Society. Drs Snead, Zheng, and Ngo-Metzger have no conflicts to disclose.  \nFunding: National Institutes of Health/National Cancer Institute, grant I D UG1CA287011 (Dr NgoMetzger) .  \nCopyright Information  \n© 2026 The Authors. Published by The Permanente Federation LLC under the terms of the CC BY-NC-ND 4.0 license [https://](h","cbCaiqULfliyIuO4","https://ap.wps.com/l/cbCaiqULfliyIuO4","pdf",156285,"English","# Abstract\n# Point: Multicancer Detection Assays Are Promising and Likely to Be More Accessible Than Conventional Cancer Screening Tests\n## What Is a Multicancer Detection Test?\n# What Evidence Is There for the Clinical Validity of MCD Testing?","[{\"question\":\"How do multicancer detection (MCD) tests work and what do they detect?\",\"answer\":\"MCD assays use blood samples to analyze circulating cell-free DNA and other circulating tumor fragments. They aim to detect cancer signals and may provide information about the possible origin of the signal.\"},{\"question\":\"What benefits do MCD tests offer compared with conventional cancer screening?\",\"answer\":\"MCD tests may detect multiple cancer types earlier in their course, when treatment is more likely to be effective. Their blood-based approach could also improve accessibility relative to site-specific screening.\"},{\"question\":\"What potential harms and limitations are associated with MCD testing?\",\"answer\":\"Concerns include false positives causing short-term emotional distress and additional testing that may be wasteful or risky, false negatives leading to unwarranted reassurance, and overdiagnosis of indolent cancers. Limited harms reporting and unclear follow-up protocols further complicate clinical use.\"}]","Multicancer Detection Assays - Promise and Potential Harms of a Novel Cancer Screening Tool | PDF",1790100263,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/701a53164694c329d9ba2af42fd328db.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c79b3a9633c5a49f0754e9284172c4c9.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24c9f4359a9731d7794b397dbe1d6ecb.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b72b11514549e1403a262e1053a21930.webp",980,1268]